# Manuel Romero‐Gómez

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/manuel-romero-gomez/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,222 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 103 |
| i10-index | 377 |
| Last Known Institution | Centro de Investigación Biomédica en Red |
| OpenAlex ID | https://openalex.org/A5037480677 |
| ORCID iD | https://orcid.org/0000-0001-8494-8947 |
| Works | 949 |

## Researcher papers

Showing 12 of 19.

- [A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement](https://scholariq.org/papers/a-new-definition-for-metabolic-dysfunction-associated-fatty-liver-disease-an/)
- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030](https://scholariq.org/papers/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united/)
- [Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening](https://scholariq.org/papers/elafibranor-an-agonist-of-the-peroxisome-proliferator-activated-receptor-and/)
- [Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis](https://scholariq.org/papers/age-as-a-confounding-factor-for-the-accurate-non-invasive-diagnosis-of-advanced/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-2/)
- [Advancing the global public health agenda for NAFLD: a consensus statement](https://scholariq.org/papers/advancing-the-global-public-health-agenda-for-nafld-a-consensus-statement/)
- [A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH](https://scholariq.org/papers/a-randomized-controlled-trial-of-the-pan-ppar-agonist-lanifibranor-in-nash/)
- [The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology](https://scholariq.org/papers/the-predict-study-uncovers-three-clinical-courses-of-acutely-decompensated/)
- [Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials](https://scholariq.org/papers/selonsertib-for-patients-with-bridging-fibrosis-or-compensated-cirrhosis-due-to/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)

## Researcher university

- [Centro de Investigación Biomédica en Red](https://scholariq.org/institutions/centro-de-investigacion-biomedica-en-red/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.